Literature DB >> 18568693

Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARalpha null mice.

Patience Obih1, Adebayo O Oyekan.   

Abstract

This study evaluated the role of PPARalpha in renal function and whether PPARalpha knockout (KO) mice are hypertensive or salt-sensitive. We hypothesize that PPARalpha modulation of ion transport defines the capacity for sodium excretion (U(Na)V). PPARalpha KO and wild-type (WT) mice were placed on a normal salt (NS, 0.5% NaCl) or high salt (8% NaCl, HS) diet for 28 days and mean arterial blood pressure (MABP) and heart rate (HR) determined. In a group of anesthetized animals on NS diet, pressure natriuresis (P/N) was determined and in another group, acute sodium load (0.9% NaCl) was administered and U(Na)V compared in mice pretreated with amiloride (200 microg/kg) or hydrochlorothiazide (3 mg/kg), in vivo measurements of sodium hydrogen exchanger or Na-Cl-cotransporter activity, respectively. MABP and HR were similar in PPARalpha KO and WT mice placed on a NS diet (116+/-6 mmHg, 587+/-40 beats/min, KO; 116+/-4 mmHg, 551+/-20 beats/min, WT). HS diet increased MABP to a greater extent in KO mice (Delta = 29+/-3 vs 14+/-3 mmHg, p<0.05) as did proteinuria (8- vs 2.5-fold, p<0.05). P/N was blunted in untreated KO mice. In response to an acute NaCl-load, U(Na)V was faster in PPARalpha KO mice (4.31+/-1.11 vs 0.77+/-0.31 micromol, p<0.05). However, U(Na)V was unchanged in hydrochlorothiazide-treated KO mice but increased 6.9-fold in WT mice. Similarly, U(Na)V was less in amiloride-treated KO mice (3.4- vs 15.5-fold). These data suggest that PPARalpha participates in pressure natriuresis and affects Na transport via amiloride- and thiazide-sensitive mechanisms. Thus, despite defective fatty acid oxidation, PPARalpha null mice are not hypertensive but develop salt-sensitive hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568693     DOI: 10.1080/08037050701789278

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  7 in total

Review 1.  Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney Diseases.

Authors:  David E Stec; Claudio Tiribelli; Olufunto O Badmus; Terry D Hinds
Journal:  Kidney360       Date:  2022-03-25

2.  Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension.

Authors:  Kimberly Gilbert; Hui Nian; Chang Yu; James M Luther; Nancy J Brown
Journal:  J Hypertens       Date:  2013-04       Impact factor: 4.844

3.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

4.  Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors.

Authors:  Tengis S Pavlov; John D Imig; Alexander Staruschenko
Journal:  PPAR Res       Date:  2010-06-14       Impact factor: 4.964

5.  Hypoxia-inducible factor 2α (HIF-2α) heterozygous-null mice exhibit exaggerated carotid body sensitivity to hypoxia, breathing instability, and hypertension.

Authors:  Ying-Jie Peng; Jayasri Nanduri; Shakil A Khan; Guoxiang Yuan; Ning Wang; Brian Kinsman; Damodara R Vaddi; Ganesh K Kumar; Joseph A Garcia; Gregg L Semenza; Nanduri R Prabhakar
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 12.779

6.  Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension.

Authors:  Dexter L Lee; Justin L Wilson; Rong Duan; Tamaro Hudson; Ahmed El-Marakby
Journal:  PPAR Res       Date:  2011-12-07       Impact factor: 4.964

7.  Restoration of Endothelial Function in Pparα (-/-) Mice by Tempol.

Authors:  Neerupma Silswal; Nikhil Parelkar; Jon Andresen; Michael J Wacker
Journal:  PPAR Res       Date:  2015-11-15       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.